Congratulations to Onyx Pharmaceuticals!

Accelerated FDA approval of Kyprolis™ (carfilzomib) for Injection

Anti-cancer drug gets acellerated FDA approval

Congratulations to Onyx Pharmaceuticals on the accelerated FDA approval of Kyprolis™ (carfilzomib) for Injection, a proteasome inhibitor for the treatment of patients with multiple myeloma. Read the official press release.

For some analysts take on business ramifications, see:

http://www.onclive.com/web-exclusives/FDA-Approves-Carfilzomib-for-Relapsed-Multiple-Myeloma,

http://www.fiercepharma.com/story/onyx-staffs-kyprolis-assault-myeloma-market/2012-07-23,

http://www.thepharmaletter.com/file/115113/onyx-soars-as-fda-approves-kyprolis-for-multiple-myeloma.html,

Disclaimer:  CDD’s Barry Bunin was on one of the early patents for carfilzomib:  Smyth, M. S.; Laidig, G. J; Borchardt, R. T.; Bunin, B. A.; Crews, C. M.; Musser, J. H.; Schneekloth, J. S.; Chabala, J. C.  Compounds for Enzyme Inhibition.  Patent No. US 2005/0245434 A1; issued 3 Nov 2005 (Proteolix, Inc).  Proteolix was acquired by Onyx Pharmaceuticals: http://www.onyx-pharm.com/news/onyx-pharmaceuticals-to-acquire-proteolix-inc